Products
Platform
Research
Market
Learn
Compare WhiteOak Capital Pharma and Healthcare Fund vs SBI Healthcare Opportunities Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.38 | 1.93 |
NAV | ₹14.03 | ₹433.33 |
Fund Started | 16 Jan 2024 | 04 Jun 1999 |
Fund Size | ₹442.67 Cr | ₹3933.26 Cr |
Exit Load | Exit load of 1%, if redeemed within 1 months. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.38
1.93
NAV
₹14.03
₹433.33
Fund Started
16 Jan 2024
04 Jun 1999
Fund Size
₹442.67 Cr
₹3933.26 Cr
Exit Load
Exit load of 1%, if redeemed within 1 months.
Exit load of 0.50% if redeemed within 15 days
Returns
1 Year | 7.65% | 3.27% |
3 Year | - | 25.40% |
5 Year | - | 18.81% |
1 Year
7.65%
3.27%
3 Year
-
25.40%
5 Year
-
18.81%
Holding Analysis
Equity | 98.42% | 96.36% |
Cash | -10.33% | 3.56% |
Equity
98.42%
96.36%
Cash
-10.33%
3.56%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
JB Chemicals & Pharmaceuticals Ltd. | 6.94% |
Sun Pharmaceutical Industries Ltd. | 6.81% |
Fortis Healthcare Ltd. | 6.69% |
Cipla Ltd. | 4.56% |
Laurus Labs Ltd. | 4.28% |
Krishna Institute of Medical Sciences Ltd | 4.09% |
Neuland Laboratories Ltd. | 3.20% |
Max Healthcare Institute Ltd. | 3.19% |
Sun Pharmaceutical Industries Ltd. | 3.15% |
Lupin Ltd. | 3.14% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.94% |
Divi's Laboratories Ltd. | 6.36% |
Max Healthcare Institute Ltd. | 5.67% |
Cipla Ltd. | 4.59% |
Lupin Ltd. | 4.08% |
Lonza Group Ag | 4.06% |
Fortis Healthcare Ltd. | 3.70% |
Torrent Pharmaceuticals Ltd. | 3.66% |
Gland Pharma Ltd. | 3.54% |
Mankind Pharma Ltd. | 3.34% |
Fund Manager
Name | Trupti Agrawal | Tanmaya Desai |
Start Date | 15 May 2024 | 17 May 2024 |
Name
Trupti Agrawal
Tanmaya Desai
Start Date
15 May 2024
17 May 2024
About Fund
Description | The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 16 Jan 2024 | 04 Jun 1999 |
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
16 Jan 2024
04 Jun 1999